Opinion|Videos|June 24, 2024
TRANSMET: Chemotherapy Plus Liver Transplant in Unresectable Colorectal Liver Metastases
Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.
Advertisement
Episodes in this series
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5